M2 PHARMA-January 23, 2018-Teva to Pay CTI BioPharma USD 10m Milestone Payment with FDA Approval of Trisenox
for Acute Promyelocytic Leukemia
M2 EQUITYBITES-January 18, 2018-CTI BioPharma anticipates USD10m in milestone payment for TRISENOX
in February 2018
He has successfully led and managed the late development and approval of several anticancer drugs, including Halaven, Trisenox
BANKING AND CREDIT NEWS-December 5, 2014-CTI BioPharma gets USD15m milestone payment for TRISENOX
The company's proprietary products in the United States include: AMRIX (cyclobenzaprine hydrochloride extended-release capsules), TREANDA (bendamustine hydrochloride) for Injection, FENTORA (fentanyl buccal tablet) (C-II), PROVIGIL (modafinil) Tablets (C-IV), TRISENOX
(arsenic trioxide) injection, GABITRIL (tiagabine hydrochloride), NUVIGIL (armodafinil) Tablets (C-IV) and ACTIQ (oral transmucosal fentanyl citrate) (C-II).
The company's proprietary products in the United States include: PROVIGIL(r) (modafinil) Tablets [C-IV], FENTORA(r) (fentanyl buccal tablet) [C-II], TRISENOX
injection, TREANDA, AMRIX(r) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(r) (naltrexone for extended-release injectable suspension), GABITRIL(r) (tiagabine hydrochloride), NUVIGIL(tm) (armodafinil) Tablets [C-IV] and ACTIQ(r) (oral transmucosal fentanyl citrate) [C-II].
Food and Drug Administration (FDA) approved the drug Trisenox
(arsenic trioxide; Cell Therapeutics, Inc.
SYNRIBO joins TREANDA and TRISENOX
as important hematologic treatment options in the Teva Oncology portfolio.
M2 PHARMA-January 18, 2018-CTI BioPharma anticipates USD10m in milestone payment for TRISENOX
in February 2018
M2 EQUITYBITES-June 15, 2017-CTI BioPharma accepts USD10m milestone payment for TRISENOX
I am very proud of these accomplishments, including, TRISENOX
(arsenic trioxide) now the standard of care in treating patients with a rare form of leukemia; expanding the indication for ZEVALIN (ibritumomab tiuxetan), the first approved radio-immunotherapy for patients with a chronic form of lymphoma; and PIXUVRI (pixantrone), the first and only treatment approved for patients with relapsed aggressive B-cell non-Hodgkin lymphoma.
M2 EQUITYBITES-December 14, 2015-CTI BioPharma wins USD10m milestone payment for TRISENOX
from Teva Pharmaceutical